Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Original Article

Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea

Clinical and Molecular Hepatology 2021;27(4):603-615.
Published online: September 8, 2021

1Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2Department of Radiology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea

3Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea

Corresponding author : Jong Man Kim Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea Tel: +82-2-3410-1719, Fax: +82-2-3410-0040 E-mail: yjongman21@gmail.com
Kyunga Kim Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea Tel: +82-2-3410-6745, Fax: +82-2-3410-6745 E-mail: kyunga.j.kim@samsung.com

Kyeong Deok Kim and Ji Eun Lee contributed equally to this study as cofirst authors.


Editor: Dong Jin Joo, Yonsei University College of Medicine, Korea

• Received: May 16, 2021   • Revised: August 25, 2021   • Accepted: September 7, 2021

Copyright © 2021 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 12,007 Views
  • 164 Download
  • 9 Web of Science
  • 9 Crossref
  • 8 Scopus
prev next

Citations

Citations to this article as recorded by  Crossref logo
  • KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA)
    Won-Mook Choi, Ji Won Han, Tae Hyung Kim, Miyoung Choi, Moon Haeng Hur, Hyo Young Lee, Han Ah Lee, Byeong Geun Song, Heechul Nam, Jeong-Ju Yoo, Chang Hun Lee, Gi-Ae Kim, Hye Won Lee, Gwang Hyeon Choi, Young Eun Chon, Yun Bin Lee, Dong Hyun Sinn, Bo Hyun K
    Clinical and Molecular Hepatology.2026; 32(3): 1029.     CrossRef
  • Costs and health outcomes of liver transplantation for hepatocellular carcinoma: a scoping review
    Uriel Palacios-Barahona, Luis Guillermo Toro Rendón, Yuli Agudelo Berruecos, Angelica Fonseca, Diego Rojas-Gualdrón
    Cost Effectiveness and Resource Allocation.2026;[Epub]     CrossRef


  • Experimental and Clinical Transplantation.2026;[Epub]     CrossRef
  • Donor–recipient Hepatitis B serological patterns and post-transplant HBV events in pediatric living donor liver transplantation: a single-center retrospective cohort with a nested case series
    Ying Le, Haifeng Tang, Quanhai Zhang, Jiajun Weng, Lianbin Huang, Xiaoke Dai, Mingman Zhang
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trap
    Mauro Viganò, Roberta D’Ambrosio, Ciro Celsa, Agostino Colli, Nicola Coppola, Bruno Daniele, Elisabetta Degasperi, Gianpiero D’Offizi, Vito Di Marco, Stefano Fagiuoli, Martina Gambato, Corrado Girmenia, Paolo Grossi, Pietro Lampertico, Andrea Lauterio, Ma
    Digestive and Liver Disease.2025; 57(12): 2257.     CrossRef
  • Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen
    Yoshihiko Yano, Itsuko Sato, Takamitsu Imanishi, Ryutaro Yoshida, Takanori Matsuura, Yoshihide Ueda, Yuzo Kodama
    Diagnostics.2024; 14(7): 728.     CrossRef
  • Survival after liver transplantation from hepatitis B-core positive donors at a quaternary care hospital in Brazil
    Fabiana Siroma, Edson Abdala, Stefanie Lima do Nascimento Castro, Wellington Andraus, Luiz Augusto Carneiro D´Álbuquerque, Alice Tung Wan Song
    The Brazilian Journal of Infectious Diseases.2024; 28(6): 104384.     CrossRef
  • Long-term outcomes of active vaccination against de novo hepatitis B among pediatric recipients of living donor liver transplantations with anti-HBc (+) grafts: a retrospective case–control study
    Chee-Chien Yong, Yu-Hung Lin, Wendell Z. Espinosa, I-Hsuan Chen, Shih-Ho Wang, Yi-Chia Chan, Chao-Long Chen, Chih-Che Lin
    International Journal of Surgery.2024; 110(10): 6702.     CrossRef
  • Cost-effectiveness of Kidney Transplantation From Donors at Increased Risk of Blood-borne Virus Infection Transmission
    Karan K. Shah, Melanie Wyld, James A. Hedley, Karen M.J. Waller, Nicole De La Mata, Angela C. Webster, Rachael L. Morton
    Transplantation.2023; 107(9): 2028.     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
Clin Mol Hepatol. 2021;27(4):603-615.   Published online September 8, 2021
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
Clin Mol Hepatol. 2021;27(4):603-615.   Published online September 8, 2021
Close

Figure

  • 0
  • 1
  • 2
  • 3
  • 4
Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
Image Image Image Image Image
Figure 1. Flow chart of the patient selection process and allocation of anti-HBc-positive grafts. LT, liver transplantation; anti-HBc, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; anti-HBs, hepatitis B surface antibody; HBV, hepatitis B virus.
Figure 2. Patient and graft survival stratified by donor anti-HBc status. (A) Patient survival stratified by donor anti-HBc status. (B) Graft survival stratified by donor anti-HBc status. (C) Patient survival stratified by donor anti-HBc status in high MELD (≥35) patients. (D) Graft survival stratified by donor anti-HBc status in high MELD (≥35) patients. Group comparisons were performed using Kaplan-Meier and log-rank tests. Anti HBc, hepatitis B core antibody; MELD, model for end-stage liver disease.
Figure 3. Patient survival and disease-free survival rates in HBV recipients who underwent LT due to HCC stratified by donor anti-HBc status. (A) Patient survival in HBV recipients who underwent LT due to HCC stratified by donor anti-HBc status. (B) Disease-free survival rates in HBV recipients who underwent LT due to HCC stratified by donor anti-HBc status. Group comparisons were performed using Kaplan-Meier and log-rank tests. Anti-HBc, hepatitis B core antibody; HBV, hepatitis B virus; LT, liver transplantation; HCC, hepatocellular carcinoma.
Figure 4. Distributions of the year of last HBIG order and analysis of cumulative cost between HBIG and NAs in non-HBV recipients with anti-HBc positive donors. (A) Distribution of the year of last HBIG order in non-HBV recipients with anti-HBc positive donors. (B) Analysis of cumulative cost between HBIG and NAs without insurance in non-HBV recipients with anti-HBc positive donors. (C) Analysis of cumulative cost to be paid by patient between HBIG and NAs when only HBIG is covered by insurance in non-HBV recipients with anti-HBc positive donors. (D) Analysis of cumulative cost to be paid by patient between HBIG and NAs when both are covered by insurance in non-HBV recipients with anti-HBc positive donors. HBIG, hepatitis B immunoglobulin; anti-HBc, hepatitis B core antibody; NAs, nucleos(t)ide analogues; HBV, hepatitis B virus.
Graphical abstract
Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
Anti-HBc-positive group (n=457) Anti-HBc-negative group (n=898) P-value
Donor characteristic
  Age (years) 41.3±11.9 29.6±10.3 <0.001
Sex, male 260 (56.9) 620 (69.0) <0.001
BMI (kg/m2) 23.5±3.1 23.1±3.1 0.010
Living donors 417 (91.2) 854 (95.1) 0.005
Recipient characteristic
Age (years) 51.3±9.9 52.5±8.5 0.027
Sex, male 334 (73.1) 726 (80.8) 0.001
BMI (kg/m2) 24.4±3.8 24.4±3.5 0.938
Transplant indication 0.039
  Acute 24 (5.3) 37 (4.1)
Acute on chronic 38 (8.3) 46 (5.1)
Cirrhosis 395 (86.4) 815 (90.8)
MELD score 19.2±10.5 17.7±10.1 0.009
HBV infection 348 (76.1) 625 (69.6) 0.011
HCV infection 23 (5.0) 44 (4.9) 0.915
HCC 0.815
No HCC 197 (43.1) 371 (41.3)
Within the Milan criteria 179 (39.2) 361 (40.2)
Beyond the Milan criteria 81 (17.7) 166 (18.5)
Warm ischemic time (minutes) 38.4±19.4 38.2±17.6 0.881
Cold ischemic time (minutes) 95.0±63.0 97.4±66.0 0.537
Operation time (minutes) 552.2±117.6 553.2±128.0 0.887
Day 0 graft biopsy, steatosis
Macrovesicular fatty change >10% 72 (15.8) 94 (10.5) 0.005
Microvesicular fatty change >10% 124 (27.1) 195 (21.7) 0.026
Postoperative ICU stay period (days) 9.2±11.4 8.2±7.3 0.105
Hospitalization period (days) 41.9±37.7 37.7±28.6 0.033
Complication rate 210 (46.0) 441 (49.1) 0.271
Severe complication within 30 days* 157 (34.4) 303 (33.7) 0.822
Recipient mortality within 30 days 13 (2.8) 27 (3.0) 0.868
Anti-HBc-positive group (n=457) Anti-HBc-negative group (n=898) Total
Total number of graft losses 156 (34.1) 241 (26.8) 397
Liver complication
  Vascular complication 18 (11.5) 17 (7.1) 35
Biliary complication 16 (10.3) 15 (6.2) 31
Rejection 5 (3.2) 15 (6.2) 20
Alcoholic cirrhosis 1 (0.6) 2 (0.8) 3
Other 6 (3.9) 11 (4.6) 17
Recurrence of original disease
HBV infection 2 (1.3) 0 (0.0) 2
HCV infection 1 (0.6) 4 (1.7) 5
PBC/PSC 0 (0.0) 1 (0.4) 1
Malignancy
Recurrence of original tumor 42 (26.9) 80 (33.2) 122
De novo solid tumor 5 (3.2) 7 (2.9) 12
Post-transplanted lymphoproliferative disease 1 (0.6) 2 (0.8) 3
Patient death from other causes 59 (37.8) 87 (36.1) 146
Variable Univariable
Multivariable
HR (95% CI) P-value HR (95% CI) P-value
Donor age 1.008 (0.999–1.016) 0.069
Male donor 0.858 (0.694–1.059) 0.154
Donor BMI 1.018 (0.987–1.051) 0.259
Living donor 1.212 (0.780–1.883) 0.392
Anti-HBc-positive graft 1.185 (0.961–1.461) 0.113 1.200 (0.972–1.481) 0.089
Recipient age 1.003 (0.991–1.015) 0.600
Male recipient 1.207 (0.929–1.568) 0.158
Recipient BMI 0.970 (0.941–1.000) 0.049 0.970 (0.940–1.000) 0.048
Transplant indication 0.163
 Acute 1 (reference)
 Acute on chronic 1.415 (0.768–2.605) 0.266
 Cirrhosis 0.978 (0.592–1.616) 0.931
Recipient MELD score 1.007 (0.997–1.017) 0.179
Recipient HCC <0.001 <0.001
 No HCC 1 (reference) 1 (reference)
 Within the Milan criteria 1.102 (0.870–1.397) 0.420 1.255 (0.980–1.608) 0.089
 Beyond the Milan criteria 1.953 (1.502–2.539) <0.001 2.158 (1.640–2.840) <0.001
Recipient HBV infection 0.766 (0.614–0.956) 0.018 0.700 (0.554–0.885) 0.003
Recipient HCV infection 1.692 (1.151–2.487) 0.007 1.263 (0.817–1.951) 0.294
Day 0 graft biopsy, steatosis
 Macrovesicular fatty change >10% 1.050 (0.781–1.412) 0.747
 Microvesicular fatty change >10% 0.955 (0.754–1.210) 0.702
Cold ischemic time 1.000 (0.998–1.001) 0.921
Warm ischemic time 0.999 (0.993–1.005) 0.627
Severe complication within 30 days* 2.299 (1.873–2.823) <0.001 2.183 (1.776–2.683) <0.001
Rejection episode 0.951 (0.729–1.242) 0.713
Variable Univariable
Multivariable
HR (95% CI) P-value HR (95% CI) P-value
Donor age 1.011 (1.003–1.019) 0.007 1.010 (1.002–1.018) 0.016
Male donor 0.854 (0.696–1.047) 0.128
Donor BMI 1.021 (0.990–1.052) 0.182
Living donor 1.254 (0.816–1.928) 0.302
Anti-HBc positive graft 1.228 (1.004–1.502) 0.046 1.138 (0.906–1.429) 0.266
Recipient age 0.999 (0.988–1.010) 0.820
Male recipient 1.186 (0.922–1.524) 0.184
Recipient BMI 0.962 (0.934–0.991) 0.011 0.964 (0.936–0.993) 0.015
Transplant indication 0.254
  Acute 1 (reference)
Acute on chronic 1.363 (0.752–2.473) 0.308
Cirrhosis 0.995 (0.611–1.620) 0.170
Recipient MELD score 1.007 (0.997–1.016) 0.170
Recipient HCC <0.001 <0.001
No HCC 1 (reference) 1 (reference)
Within the Milan criteria 1.103 (0.879–1.384) 0.396 1.238 (0.977–1.568) 0.137
Beyond the Milan criteria 1.818 (1.407–2.349) <0.001 1.950 (1.493–2.547) <0.001
Recipient HBV infection 0.794 (0.640–0.985) 0.036 0.774 (0.617–0.973) 0.028
Recipient HCV infection 1.571 (1.070–2.308) 0.021 1.223 (0.794–1.883) 0.362
Day 0 graft biopsy (steatosis)
Macrovesicular fatty change >10% 1.049 (0.789–1.395) 0.743
Microvesicular fatty change >10% 0.969 (0.801–1.259) 0.969
Cold ischemic time 1.000 (0.998–1.001) 0.881
Warm ischemic time 0.999 (0.993–1.005) 0.719
Severe complication within 30 days* 2.410 (1.976–2.937) <0.001 2.323 (1.904–2.836) <0.001
Rejection episode 1.038 (0.807–1.334) 0.773
Table 1. Clinical characteristics of donors and recipients according to donor anti-HBc status

Values are presented as mean±standard deviation or number (%).

Anti-HBc, hepatitis B core antibody; BMI, body mass index; MELD, model for end stage liver disease; HBV, hepatitis B virus; HCV, hepatitis c virus; HCC, hepatocellular carcinoma; ICU, intensive care unit.

Clavien-Dindo classification ≥ grade 3a.

Table 2. Causes of graft loss in the whole cohort

Values are presented as number (%).

Statistical analysis was not performed to determine the cause of graft loss.

Anti-HBc, hepatitis B core antibody; HBV, hepatitis B virus; HCV, hepatitis c virus; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.

Table 3. Univariable and multivariable analyses of risk factors for patient survival

HR, hazard ratio; CI, confidence interval; BMI, body mass index; anti-HBc, hepatitis B core antibody; MELD, model for end stage liver disease; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis c virus.

Clavien-Dindo classification ≥ grade 3a.

Table 4. Univariable and multivariable analyses of risk factors for graft survival

HR, hazard ratio; CI, confidence interval; BMI, body mass index; anti-HBc, hepatitis B core antibody; MELD, model for end stage liver disease; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis c virus.

Clavien-Dindo classification ≥ grade 3a.